Parse Biosciences and Graph Therapeutics launched a strategic collaboration to build a large‑scale immune cell perturbation atlas. Graph will generate patient‑derived disease models via its lab‑in‑the‑loop platform while Parse applies its GigaLab single‑cell whole‑transcriptome sequencing to profile hundreds of millions of cells under systematic perturbations. The partners aim to map immune and tissue interactions that drive immune diseases, producing a discovery resource to de‑risk targets and streamline drug development. Parse was recently acquired by Qiagen, positioning the dataset for broad translational use.